Share
Janssen and Johnson & Johnson to Provide Webcast Presentation of ZYTIGA® (abiraterone acetate) Phase 3 Clinical Data Presented at the American Society of Clinical Oncology Annual Meeting
Janssen and Johnson & Johnson to Provide Webcast Presentation of ZYTIGA® (abiraterone acetate) Phase 3 Clinical Data Presented at the American Society of Clinical Oncology Annual Meeting
Share

New Brunswick, NJ (May 25, 2012) -- Johnson & Johnson will provide a pre-recorded webcast for investors and other interested parties on Saturday, June 2 at approximately 10:00 a.m., Eastern Time, to coincide with the American Society of Clinical Oncology’s (ASCO) Annual Meeting in Chicago, Ill.

Results from pre-specified interim analyses of COU-AA-302, a randomized, phase 3 study of abiraterone acetate in chemotherapy-naive patients with metastatic castration-resistant prostate cancer, will be shown for the first time at ASCO.

The pre-recorded webcast with management from the Company’s Janssen pharmaceutical subsidiaries, will provide an update on the results of the COU-AA-302 study and an update on the initial launch of ZYTIGA® (abiraterone acetate).

The webcast/podcast and replay can be accessed by visiting the Johnson & Johnson website at www.investor.jnj.com and clicking on “Webcasts/Presentations.”

###

Press Contacts:
Al Wasilewski
(732) 524-1130

Bill Price
(732) 524-6623

Investor Contacts:
Stan Panasewicz
(732) 524-2524

Louise Mehrotra
(732) 524-6491

This site uses cookies as described in our Cookie Policy. Please click the "Accept" button or continue to use our site if you agree to our use of cookies.
You are now leaving jnj.com. The site you’re being redirected to is a branded pharmaceutical website. Please click below to continue to that site.
Continue